{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:59:51Z","timestamp":1790049591653,"version":"4.0.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>In the setting of metastatic or locally advanced adrenocortical carcinoma, a limited number of therapies are available and their efficacy is generally below modest. The backbone of treatment remains surgery, even for metastatic disease, whenever it is possible, and mitotane. Chemotherapy can be used with limited results. A small subset of patients with adrenocortical carcinoma may have high mutational burden and harbor mutations in mismatch-repair genes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a 40-year old and a 28-year-old female patients with metastatic adrenocortical carcinoma refractory to multiple treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Next-generation sequencing detected high mutational burden (&gt;10\u200amutations\/megabase) in both patients, one of them with <jats:italic toggle=\"yes\">MSH2<\/jats:italic> mutation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>They were treated with pembrolizumab (100 to 200\u200amg every 3 weeks).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient harboring a <jats:italic toggle=\"yes\">MSH2<\/jats:italic> mutation experienced a long-term complete response after pembrolizumab, while the patient with high mutational burden and absence of mismatch repair deficiency did not have any response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>To the best of our knowledge, this is the first report in the literature of a durable complete response after pembrolizumab in a patient with metastatic adrenocortical carcinoma. Differences in therapy sequencing, possibly abscopal effect related to multiple previous radiotherapy exposition, predictive values of high mutational burden and mutations in mismatch-repair genes are discussed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013517","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T19:17:37Z","timestamp":1545938257000},"page":"e13517","source":"Crossref","is-referenced-by-count":24,"title":["Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden"],"prefix":"10.1097","volume":"97","author":[{"given":"Jose Mauricio","family":"Mota","sequence":"first","affiliation":[{"name":"Instituto do Cancer do Estado de S\u00e3o Paulo, University of Sao Paulo"},{"name":"Instituto D\u2019Or de Ensino e Pesquisa, Sao Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana Guimar\u00e3es","family":"Sousa","sequence":"additional","affiliation":[{"name":"Instituto do Cancer do Estado de S\u00e3o Paulo, University of Sao Paulo"},{"name":"Instituto D\u2019Or de Ensino e Pesquisa, Sao Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ignez","family":"Braghiroli","sequence":"additional","affiliation":[{"name":"Instituto do Cancer do Estado de S\u00e3o Paulo, University of Sao Paulo"},{"name":"Instituto D\u2019Or de Ensino e Pesquisa, Sao Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Ten\u00f3rio","family":"Siqueira","sequence":"additional","affiliation":[{"name":"Instituto do Cancer do Estado de S\u00e3o Paulo, University of Sao Paulo"},{"name":"Instituto D\u2019Or de Ensino e Pesquisa, Sao Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Evangelista Bezerra","family":"Neto","sequence":"additional","affiliation":[{"name":"Instituto do Cancer do Estado de S\u00e3o Paulo, University of Sao Paulo"},{"name":"Instituto D\u2019Or de Ensino e Pesquisa, Sao Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Chapchap","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio Libanes, Sao Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana A. de Oliveira","family":"Hoff","sequence":"additional","affiliation":[{"name":"Instituto do Cancer do Estado de S\u00e3o Paulo, University of Sao Paulo"},{"name":"Instituto D\u2019Or de Ensino e Pesquisa, Sao Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo M.","family":"Hoff","sequence":"additional","affiliation":[{"name":"Instituto do Cancer do Estado de S\u00e3o Paulo, University of Sao Paulo"},{"name":"Instituto D\u2019Or de Ensino e Pesquisa, Sao Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur J Cancer"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1210\/jc.2008-2291","article-title":"Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review","volume":"94","author":"Golden","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s002689900442","article-title":"Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up","volume":"22","author":"Khorram-Manesh","year":"1998","journal-title":"World J Surg"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2013-2856","article-title":"Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma","volume":"99","author":"Else","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-20230914","first-page":"371","article-title":"Prognostic factors in adrenocortical carcinoma: data from a large Polish series","volume":"28","author":"Nowak","year":"2018","journal-title":"Polish Arch Intern Med"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jamcollsurg.2015.12.013","article-title":"Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US adrenocortical carcinoma group","volume":"222","author":"Postlewait","year":"2016","journal-title":"J Am Coll Surg"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10434-999-0719-7","article-title":"Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma","volume":"6","author":"Schulick","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/jso.23015","article-title":"Operative management for recurrent and metastatic adrenocortical carcinoma","volume":"105","author":"Datrice","year":"2012","journal-title":"J Surg Oncol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1245\/s10434-011-1564-z","article-title":"Liver resection and ablation for metastatic adrenocortical carcinoma","volume":"18","author":"Ripley","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/s-0028-1087178","article-title":"Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer--a case report and review of the literature","volume":"117","author":"Bauditz","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.11084","article-title":"Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases","volume":"97","author":"Wood","year":"2003","journal-title":"Cancer"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2005-2639","article-title":"Clinical review: Adrenocortical carcinoma: clinical update","volume":"91","author":"Allolio","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1210\/jc.2014-3282","article-title":"Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma","volume":"100","author":"Juhlin","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41379-018-0042-6","article-title":"Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas","volume":"31","author":"Vatrano","year":"2018","journal-title":"Mod Pathol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a lynch syndrome-associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10689-010-9416-8","article-title":"Adrenocortical carcinoma, an unusual extracolonic tumor associated with Lynch II syndrome","volume":"10","author":"Medina-Arana","year":"2011","journal-title":"Fam Cancer"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/1471-2407-14-561","article-title":"A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers","volume":"14","author":"Halperin","year":"2014","journal-title":"BMC Cancer"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O'Sullivan","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"1758835918768240","DOI":"10.1177\/1758835918768240","article-title":"Radiotherapy and checkpoint inhibitors: a winning new combination?","volume":"10","author":"Ko","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","article-title":"PD-1 restrains radiotherapy-induced abscopal effect","volume":"3","author":"Park","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1002\/eji.201444879","article-title":"Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis","volume":"44","author":"Dimeloe","year":"2014","journal-title":"Eur J Immunol"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-17-0895","article-title":"Low-dose cyclophosphamide induces antitumor T-Cell responses, which associate with survival in metastatic colorectal cancer","volume":"23","author":"Scurr","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201812280-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:06:18Z","timestamp":1694718378000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201812280-00002"}},"subtitle":["Two case reports"],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":32,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013517","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}